News stories about Auris Medical Holding AG (NASDAQ:EARS) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Auris Medical Holding AG earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.8418087172429 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Auris Medical: Clinical Updates and Potential Catalysts (finance.yahoo.com)
- What You Must Know About Auris Medical Holding AG’s (EARS) Financial Strength (finance.yahoo.com)
- Celldex Therapeutics, Inc. (CLDX) has a value of $2.38 per share While Auris Medical Holding AG (EARS) is stand at … – Stocks Gallery (stocksgallery.com)
- Who is showing interest in Auris Medical Holding AG (EARS) stock Buyer or Seller? – Wall Street Morning (wallstreetmorning.com)
- -$0.20 EPS Expected for Auris Medical Holding AG (EARS) This Quarter (americanbankingnews.com)
Separately, Zacks Investment Research raised shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research report on Wednesday, August 30th.
Auris Medical Holding AG (EARS) traded up $0.05 during trading on Tuesday, hitting $0.73. 1,251,100 shares of the stock traded hands, compared to its average volume of 380,879. Auris Medical Holding AG has a 1-year low of $0.60 and a 1-year high of $1.50. The company has a debt-to-equity ratio of 1.43, a current ratio of 2.56 and a quick ratio of 2.56.
Auris Medical Holding AG (NASDAQ:EARS) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.09. sell-side analysts forecast that Auris Medical Holding AG will post -0.68 earnings per share for the current year.
Auris Medical Holding AG Company Profile
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.